Abaloparatide - Generic Drug Details

✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions

What are the generic drug sources for abaloparatide and what is the scope of patent protection?

Abaloparatide is the generic ingredient in one branded drug marketed by Radius Health Inc and is included in one NDA. There are five patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Abaloparatide has fifty patent family members in twenty-six countries.

One supplier is listed for this compound.

Summary for abaloparatide

International Patents:	50
US Patents:	5
Tradenames:	1
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	5
Clinical Trials:	14
Drug Prices:	Drug price trends for abaloparatide
What excipients (inactive ingredients) are in abaloparatide?	abaloparatide excipients list
DailyMed Link:	abaloparatide at DailyMed

See drug prices for abaloparatide

Recent Clinical Trials for abaloparatide

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Daniel Horwitz	Phase 4
Johns Hopkins University	Phase 2
Crozer-Keystone Health System	Phase 4

See all abaloparatide clinical trials

Pharmacology for abaloparatide

Drug Class	Parathyroid Hormone-Related Peptide Analog

Anatomical Therapeutic Chemical (ATC) Classes for abaloparatide

H05AA	Parathyroid hormones and analogues
H05A	PARATHYROID HORMONES AND ANALOGUES
H05	CALCIUM HOMEOSTASIS
H	Systemic hormonal preparations, excluding sex hormones and insulins

US Patents and Regulatory Information for abaloparatide

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Try it Free
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Radius Health Inc	TYMLOS	abaloparatide	SOLUTION;SUBCUTANEOUS	208743-001	Apr 28, 2017		RX	Yes	Yes	See Plans and Pricing	See Plans and Pricing				See Plans and Pricing
Radius Health Inc	TYMLOS	abaloparatide	SOLUTION;SUBCUTANEOUS	208743-001	Apr 28, 2017		RX	Yes	Yes	See Plans and Pricing	See Plans and Pricing	Y			See Plans and Pricing
Radius Health Inc	TYMLOS	abaloparatide	SOLUTION;SUBCUTANEOUS	208743-001	Apr 28, 2017		RX	Yes	Yes	See Plans and Pricing	See Plans and Pricing				See Plans and Pricing
Radius Health Inc	TYMLOS	abaloparatide	SOLUTION;SUBCUTANEOUS	208743-001	Apr 28, 2017		RX	Yes	Yes	See Plans and Pricing	See Plans and Pricing				See Plans and Pricing
Radius Health Inc	TYMLOS	abaloparatide	SOLUTION;SUBCUTANEOUS	208743-001	Apr 28, 2017		RX	Yes	Yes	See Plans and Pricing	See Plans and Pricing	Y			See Plans and Pricing
Radius Health Inc	TYMLOS	abaloparatide	SOLUTION;SUBCUTANEOUS	208743-001	Apr 28, 2017		RX	Yes	Yes	See Plans and Pricing	See Plans and Pricing				See Plans and Pricing
Radius Health Inc	TYMLOS	abaloparatide	SOLUTION;SUBCUTANEOUS	208743-001	Apr 28, 2017		RX	Yes	Yes	See Plans and Pricing	See Plans and Pricing				See Plans and Pricing
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

EU/EMA Drug Approvals for abaloparatide

Subscribe to access the full database, or Try it Free
Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Radius International Ltd	Eladynos	abaloparatide	EMEA/H/C/004157 Treatment of osteoporosis.	Refused	no	no	no		2019-01-07
>Company	>Drugname	>Inn	>Product Number / Indication	>Status	>Generic	>Biosimilar	>Orphan	>Marketing Authorisation	>Marketing Refusal

International Patents for abaloparatide

Subscribe to access the full database, or Try it Free
Country	Patent Number	Title	Estimated Expiration
South Korea	20210120009	부갑상선 호르몬(PTH) 및 부갑상선 호르몬-관련 펩티드(PTHRP) 유사체에 대한 중화 항체의 검출 방법	See Plans and Pricing
China	101578093	Method of drug delivery for bone anabolic protein	See Plans and Pricing
European Patent Office	3908605	PROCÉDÉS DE DÉTECTION D'ANTICORPS DE NEUTRALISATION DIRIGÉS CONTRE L'HORMONE PARATHYROÏDE (PTH) ET ANALOGUE DE PEPTIDE LIÉ À L'HORMONE PARATHYROÏDE (PTHRP) (METHODS FOR DETECTING NEUTRALIZING ANTIBODIES TO PARATHYROID HORMONE (PTH) AND PARATHYROID HORMONE-RELATED PEPTIDE (PTHRP) ANALOG)	See Plans and Pricing
Portugal	2073789		See Plans and Pricing
Australia	2020207653	Methods for detecting neutralizing antibodies to parathyroid hormone (PTH) and parathyroid hormone-related peptide (PTHrP) analog	See Plans and Pricing
Japan	2010505835		See Plans and Pricing
Portugal	2957278		See Plans and Pricing
>Country	>Patent Number	>Title	>Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.